Thapsigargin, Ca2+-ATPase inhibitor (ab120286)
Key features and details
- Ca2+-ATPase inhibitor
- CAS Number: 67526-95-8
- Soluble in DMSO to 100 mM
- Form / State: Solid
- Source: Thapsia garganica
製品の概要
-
製品名
Thapsigargin, Ca2+-ATPase inhibitor -
製品の詳細
Ca2+-ATPase inhibitor -
生理活性の詳細
A potent, cell-permeable Ca2+-ATPase inhibitor. Releases Ca2+ by inhibiting endoplasmic reticular Ca2+-ATPase (IC50 = 4-13 nM). Both tumorogenic and apoptotic actions reported.
-
CAS 番号
67526-95-8 -
構造式
製品の特性
-
体系名
(3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-(Acetyloxy)-2,3,3a,4,5,6,6a,7,8,9b-decahydro-3,3a-dihydroxy-3,6,9-trimethyl-8-[[(2Z)-2-methyl-1-oxo-2-butenyl]oxy]-2-oxo-4-(1-oxobutoxy)azuleno[4,5-b]furan-7-yl octanoate -
分子量
650.76 -
分子式
C34H50O12 -
PubChem 登録番号
446378 -
保存方法
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
溶解性
Soluble in DMSO to 100 mM -
使用に関する注意
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES 線形表記
CC=C(C)C(=O)O[C@@H]3[C@@H](OC(=O)CCCCCCC)[C@H]1C([C@@H]2OC(=O)[C@](O)(C)[C@@]2(O)[C@H](C[C@]1(C)OC(C)=O)OC(=O)CCC)=C3C -
由来
Thapsia garganica
-
研究分野
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab120286の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
| アプリケーション | Abreviews | 特記事項 |
|---|---|---|
| Functional Studies |
Use at an assay dependent concentration.
|
| 特記事項 |
|---|
|
Functional Studies
Use at an assay dependent concentration. |
画像
-
Chemical Structure - Thapsigargin, Ca2+-ATPase inhibitor (ab120286)2D chemical structure image of ab120286, Thapsigargin, Ca2+-ATPase inhibitor
-
Functional Studies - Thapsigargin, Ca2+-ATPase inhibitor (ab120286)ab58668 staining ATF3 in serum starved A549 cells treated with thapsigargin (ab120286), by ICC/IF. Increase of ATF3 correlates with increased concentration of thapsigargin, as described in literature.
The cells were incubated at 37°C for 1h in media containing different concentrations of ab120286 (thapsigargin) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab58668 (10 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-mouse polyclonal antibody (ab96879) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
参考文献 (36)
ab120286 は 36 報の論文で使用されています。
- Du Y et al. Tex2 is required for lysosomal functions at TMEM55-dependent ER membrane contact sites. J Cell Biol 222:N/A (2023). PubMed: 36705603
- Bae E et al. Integrin a3ß1 promotes vessel formation of glioblastoma-associated endothelial cells through calcium-mediated macropinocytosis and lysosomal exocytosis. Nat Commun 13:4268 (2022). PubMed: 35879332
- Efremov AK et al. Application of piconewton forces to individual filopodia reveals mechanosensory role of L-type Ca2+ channels. Biomaterials 284:121477 (2022). PubMed: 35395455
- Qiu K et al. Ryanodine receptor RyR1-mediated elevation of Ca2+ concentration is required for the late stage of myogenic differentiation and fusion. J Anim Sci Biotechnol 13:9 (2022). PubMed: 35144690
- Zhang P et al. Protein C receptor maintains cancer stem cell properties via activating lipid synthesis in nasopharyngeal carcinoma. Signal Transduct Target Ther 7:46 (2022). PubMed: 35169126